There is one clinical trial.
The noval coronavirus disease 2019 (COVID-19) would cause physical and psychological dysfunctions in infected patients. We expect that an intelligence-based remote pulmonary rehabilitation scheme could improve patients' health status after hospital discharge. The intelligence-based remote pulmonary rehabilitation program is designed in a real-world and prospective manner, aiming to evaluate the efficacy of rehabilitation among 200 patients in the epicenter of China (Wuhan City) according to their varied adherence. An eight-week rehabilitation scheme, including two weeks for physicians and physiotherapists remotely guided training, and six weeks for patient self-management, will be addressed. The primary outcome of current study is six-minute walking distance and lung function, and secondly respiratory muscle strength, physical fitness assessment, symptoms and quality of life, etc. will also be assessed. Recruited patients will be followed up at week 2, 4, 8 after enrollment and at month 1, 3, 6, 12 after the rehabilitation training completed, respectively. The study has been approved by the ethics committee of China-Japan Friendship Hospital and three participating centers in Wuhan City.
Description: Walking distance within six minutesMeasure: Six-minute walking distance (6MWD) Time: One year
Description: Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), etc.Measure: Pulmonary function Time: One year
Description: Maximal inspiratory pressure, maximal expiratory pressure, etc.Measure: Respiratory muscle strength Time: One year
Description: Two-minute walking test, short physical performance battery, grip strength of both upper limbs, knee extension strength of both lower limbs, etc.Measure: Physical fitness assessment Time: One year
Description: Modified British Medical Research Council (mMRC) dyspnea scale, etc.Measure: Symptom Time: One year
Description: Self-training depression scale (SDS) and self-rating anxiety scale (SAS)Measure: Psychological evaluation Time: One year
Description: 36-item short-form health survey (SF-36), etc.Measure: Quality of life Time: One year
Description: International physical activity questionnaire (IPAQ)Measure: Physical activity Time: One year
Description: Proportions of returning to routine work and normal lifeMeasure: Proportion of returning to society Time: One year
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports